Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

Fig. 1

Kaplan-Meier analysis of disease-free and overall survival. The solid line represents overall survival, and the dotted line represents disease-free survival. DFS was calculated from start of treatment to the date of first appearance of disease relapse, or death from any cause. DFS and OS were estimated using the product-limit method of Kaplan and Meier; 95% confidence interval was calculated using Greenwoodā€™s formula

Back to article page